All Stories

As chikungunya launch looms, Bavarian Nordic CEO tips travel health to become the company's dominant business

While the ebb and flow of mpox outbreaks may have taken a toll on Bavarian Nordic’s 2024 sales performance, the year also validated, in large part, the travel vaccines business the Danish company has been building out since the start of the decade.

Mar 6, 2025 - 15:47
 0
As chikungunya launch looms, Bavarian Nordic CEO tips travel health to become the company's dominant business
While the ebb and flow of mpox outbreaks may have taken a toll on Bavarian Nordic’s 2024 sales performance, the year also validated, in large part, the travel vaccines business the Danish company has been building out since the start of the decade.
Read More

Tags:

Previous Article

EXCLUSIVE: Reimagining retail spaces through digital innovation

Next Article

Regulatory tracker: ARS' allergy nasal spray neffy approved for use in children

Related Posts

Few psych drugs from past decade are on HCPs’ radars: survey

Few psych drugs from past decade are on HCPs’ radars: s...

Apr 10, 2025  0

Novartis plots 427 layoffs in New Jersey as looming Entresto patent cliff sparks marketing refresh

Novartis plots 427 layoffs in New Jersey as looming Ent...

Mar 18, 2025  0

RFK Jr. looks to find cause of 'autism epidemic' by September through massive HHS research push

RFK Jr. looks to find cause of 'autism epidemic' by Sep...

Apr 11, 2025  0